Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Redhill Biopharma Ltd (NASDAQ:RDHL)

Delayed Data
As of 2:03pm ET
 -0.2101 / -2.08%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

RedHill Biopharma Ltd. is a biopharmaceutical company. Primarily, it is focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. Its current pipeline of proprietary products includes: (i) RHB-105-an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104-an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and an ongoing proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA (RHB-102)-a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106-an encapsulated bowel preparation licensed to Salix Pharmaceuticals Ltd.; (v) YELIVA (ABC294640)-a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON-a Phase II-stage first-in-class uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumors; (vii) RP101 is a Phase II-stage first-in-class Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (viii) RIZAPORT (RHB-103)-an oral thin film formulation of rizatriptan for acute migraines and with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Contact Information

RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv Tel Aviv 64739
P:(723) 541-3131
Investor Relations:



Other institutional11.97%
Mutual fund holders1.34%
Individual stakeholders--

Top Executives

Dror Ben-AsherChairman & Chief Executive Officer
Gilead RadayChief Operating Officer
Micha Ben-ChorinChief Financial Officer
Reza FathiSenior Vice President-Research & Development
Adi FrishSenior VP-Business Development & Licensing